4D Molecular Therapeutics (FDMT) Operating Margin Growth (3y) (2023 - 2026)

4D Molecular Therapeutics (FDMT) Operating Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -204.00
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 828,504.00
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 7,261.00
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -50,506.00
7 Royalty Pharma 33.72 Bn 35.84 Bn - -2,649.00
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 9,003.00
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 30,461.00
10 4D Molecular Therapeutics 856.62 Mn 495.28 Mn - 1.14 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 1.14 Mn
Mar 31, 2026 768,654.00
Dec 31, 2025 232,042.00
Sep 30, 2025 -6.27 Mn
Jun 30, 2025 -37.88 Mn
Mar 31, 2025 -38.08 Mn
Dec 31, 2024 -558.48 Mn
Sep 30, 2024 -170.27 Mn
Jun 30, 2024 -84.91 Mn
Mar 31, 2024 -13.54 Mn
Dec 31, 2023 19.31 Mn
Sep 30, 2023 3,616.00
Jun 30, 2023 -1.30 Mn
Mar 31, 2023 -972,710.00